Avecia boosts biocatalysis R&D

Related tags Pharmaceutical drug Avecia

UK-based Avecia, Europe's largest privately owned chemicals
company, has teamed up with Germany's IEP to develop new synthetic
routes for pharmaceutical intermediates using biocatalysis.

The agreement also represents a bolstering of Avecia's activities in chiral production technology, which has developed rapidly in the last few years due to an increasing demand for chiral or single stereoisomer compounds as active ingredients in pharmaceuticals. Chiral ingredients are those that consist of just one of the two mirror-image conformations that are encountered in organic compounds.

Reduction of compounds such as ketones is a key stage in the synthesis of a number of chiral intermediates, and there is a growing movement towards the use of biocatalysts for this purpose, with new collaborations in this area between DSM and Degussa and Wacker and Prokaria, amongst others.

Under the terms of the alliance, IEP​ will perform development work for Avecia​ on various unnamed pharmaceutical intermediates, and the two companies will combine their biocatalysis process technology to develop improved bioreduction processes to produce the target compounds. Financial details were not disclosed.

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us

Products

View more

Webinars